NEW YORK--(BUSINESS WIRE)--Retrophin, Inc. (OTCQB: RTRX) today announced the Company’s financial results for the quarter ended September 30, 2013. The Company’s Form 10-Q was filed on November 13, 2013.
Third Quarter 2013 and Recent Highlights
• Phase II trial initiation activities for RE-021 in focal segmental glomerulosclerosis (FSGS) are underway, with “first-patient-in” expected in December 2013. FDA has indicated the results of this Phase II trial may serve as the basis for accelerated approval.
Help employers find you! Check out all the jobs and post your resume.
